openPR Logo
Press release

Bi-specific Antibodies For Enhanced Killing of the Foreign Cells Invaders

08-12-2020 11:22 AM CET | Health & Medicine

Press release from: Kuick Resarch

The availability of bi-specific antibodies has triggered a fundamental shift in the treatment paradigm for broad spectrum disease. The big pool of data available for the complex human system and its coupling with the advanced analytics tools have helped the researchers to come up with a treatment procedure that is unique and hold maximum promising outcomes for the huge percentage of patient population in the world. Bi-specific antibodies represent a class of therapeutics that holds more therapeutic activity than any other drug class. It has the ability to bind to two different epitopes i.e. it shows a broad spectrum for treatment irrespective that it is done by a single antibody.

"Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026" Report Highlights:

• Global Bispecific Antibody Market Opportunity: > US$ 10 Billion
• Global Bispecific Antibody Market Growth: 118% CAGR (2015 -2019)
• Global Bispecific Antibody Market Growth In 2019: 280% (> US$ 1.5 Billion)
• Global Bispecific Antibody Pipeline: 333 Drug
• Commercially Available Bispecific Antibodies: 2 (Blincyto & Hemlibra)
• Hemlibra Sales & Market Share 2019: > US$ 1.4 Billion & > 80%

Download Report:
https://www.kuickresearch.com/report-global-bispecific-antibody-market-opportunity,-drug-sales--and-clinical-trials-insight-2026.php

There are various significant opportunities that are associated within the market. It has the ability to transform the antibody class of the drugs. The applications coupled with it have helped in earning huge business for the stakeholders that are engaged with the market. The market of bi-specific antibodies holds the potential to drive unprecedented scenario that has been lacking in the market for a prolonged period of time. The better outcomes related with the use of the antibodies as well as improvement in the overall applications offerings are inclining thousands of researchers, physicians and clinicians towards making it patient centric.

The market is hold by a strong backbone of clinical insights. There are a number of drugs that are currently available in the market and same is for the clinical pipeline that are currently getting evaluated and verified for the next-generation bi-specific antibodies. The market is supported by hundreds of drugs that have been evaluated clearly in order to deliver promising benefits and opportunities to serve the patients and help the society to develop and deliver more healthcare solutions. The availability of BiTE technology by Amgen’s designed for CD3 on the T cells and the tumor cells is delivering productive advantage as the sales record of this respective technology is raising the bars for the upcoming bi-specific antibodies. The global market for the same is observing positive outlook by identifying the past opportunities as well as the opportunities that will be observed in the future.

As of now, the market is pre-dominantly comprising of all the applications that are making the market promising and centric towards the patients. The future market scenario of the market with respect to the research studies, development and commercialization of the upcoming drugs is already attracting several stakeholders, public and private investors to invest. The opportunities and the trends related to the market i.e. affordable drug price and low toxicity are estimated to drive the global bi-specific antibodies in the present and the future. The market with all the ongoing activity is estimated to be valued US$ 10 Billion by the year 2026.

Contact:
Neeraj Chawla
Research Head
neeraj@kuickresearch.com
+91-09810410366

Delhi
India

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bi-specific Antibodies For Enhanced Killing of the Foreign Cells Invaders here

News-ID: 2110489 • Views: 213

More Releases from Kuick Resarch

Global Antibody Drug Conjugate Market Sales Size Opportunity To Surpass US$ 10 B …
"Novel Cancer Antibody Drug Conjugates to Drive Cancer Therapeutics Market With More Than 290 Cancer Antibodies In Clinical Trials Pipeline Says Kuick Research" "Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs • Marketed Cancer Antibody Drug Conjugate: 9 Drugs • Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026 • Majority of Drug Trials Are For Second Line Therapy
Global Cell Therapy Market Stem Cell Therapy Market Size Sales Growth Clinical T …
Global Cell Therapy Market Size Sales Opportunity To Surpass USD 40 Billion By 2027 Says Kuick Research Report Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027 "Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027" Report Highlights: • Global Cell Therapy Market: > USD 40 Billion By 2027 • Cell Therapy Clinical Trial Insight by Indication, Company and Country • Cell Therapy Price & Product Insight By Region/Country • Clinical
Global Small Molecule Targeted Cancer Drug Market Size Sales To Reach US$ 130 Bi …
"Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Small Molecule Cancer Drug Market: > US$ 125 Billion by 2026 • USA Dominates Global Small Molecule Cancer Drug Market: >50% Share • Number of Small Molecule Cancer Drugs In Clinical Trials: >2500 Drugs • Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs • Small Molecule Drug Insight by Cancer • Clinical Trials Insight
GCC Clinical Trial Market Outlook Insight 2025
"GCC Clinical Trial Market Outlook 2025" Report Highlights: • GCC Clinical Trial Market Opportunity: >US$ 500 Million • GCC Disease Prevalence & Statistics • Saudi Arabia Dominating GCC Clinical Trial Landscape: > 500 Trials • Clinical Trials for Cancer in GCC: > 120 Trials • Guidelines For Conducting Clinical Trials by Country • Ongoing Clinical Trials Insight by Country Download Report: https://www.kuickresearch.com/report-report-report-report-report-report-report-report-gcc-clinical-trial-market-size-number--data-regulation-registration Table of Contents 1. GCC Clinical Market Regional Insights 2. GCC Clinical Trial Market Dynamics 2.1 Driving Forces for GCC Clinical Trial

All 5 Releases


More Releases for Bispecific

Bispecific Antibodies Market Opportunity Analysis, 2018-2026
Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Lung, breast and colon cancer are the wider applications of BsAb. Bispecific antibody simultaneously binds to a cytotoxic cell and target tumor cell and destroys it. Bispecific antibodies are emerging a
Bispecific Antibodies Market Plying for Significant Growth During 2023
Bispecific antibodies are recognized as artificial protein where two or more antigen recognizing elements are combining together to form a single construct. Bispecific antibodies are able to bind into two or more targets at a time. Moreover, these antibodies might bridge two targets together and are able to present high chances of gaining therapeutic effects (bring cancer cell within striking distance). The various formats of bispecific antibodies include quadromas, chemical
Bispecific Antibodies Market - Global Industry Analysis 2024
Bispecific Antibodies Market Overview Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Lung, breast and colon cancer are the wider applications of BsAb. Bispecific antibody simultaneously binds to a cytotoxic cell and target tumor cell and destroys it. Bispecific antibodies
Bispecific Antibodies Market to Grow Globally
Bispecific Antibodies Market Overview Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Lung, breast and colon cancer are the wider applications of BsAb. Bispecific antibody simultaneously binds to a cytotoxic cell and target tumor cell and destroys it. Bispecific antibodies
Bispecific Antibodies Market - Trends, Outlook, and Opportunity Analysis, 2016-2 …
Key players involved in the Bispecific antibodies market include Some of the key players in Bispecific antibodies market are Amgen, Inc., Bayer AG, Dow Pharmaceutical Solutions, ImmunGene, Inc., Immunocore Limited, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and F. Hoffmann-La Roche AG. Get Free PDF Research Brochure for more Professional and Technical Insights : https://www.coherentmarketinsights.com/insight/request-sample/19 Bispecific Antibodies Market Overview Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two
Bispecific Antibodies Market Research Report Forecast to 2015- 2023
Bispecific antibodies are recognized as artificial protein where two or more antigen recognizing elements are combining together to form a single construct. Bispecific antibodies are able to bind into two or more targets at a time. Moreover, these antibodies might bridge two targets together and are able to present high chances of gaining therapeutic effects (bring cancer cell within striking distance). The various formats of bispecific antibodies include quadromas, chemical